Free Trial
NASDAQ:HCAT

Health Catalyst (HCAT) Stock Price, News & Analysis

Health Catalyst logo
$4.33 -0.20 (-4.42%)
Closing price 04:00 PM Eastern
Extended Trading
$4.33 0.00 (0.00%)
As of 07:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Health Catalyst Stock (NASDAQ:HCAT)

Key Stats

Today's Range
$4.32
$4.64
50-Day Range
$3.97
$5.89
52-Week Range
$3.76
$9.24
Volume
614,248 shs
Average Volume
615,869 shs
Market Capitalization
$304.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.27
Consensus Rating
Moderate Buy

Company Overview

Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases. It offers services expertise solutions comprising data and analytics, domain expertise and education, tech-enabled managed, and implementation services; and opportunity analysis and prioritization, data governance, data modeling and analysis, quality and process improvement strategy, cost accounting, data abstraction, and population health strategies. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is headquartered in South Jordan, Utah.

Remove Ads

Health Catalyst Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
94th Percentile Overall Score

HCAT MarketRank™: 

Health Catalyst scored higher than 94% of companies evaluated by MarketBeat, and ranked 54th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Health Catalyst has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Health Catalyst has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Health Catalyst's stock forecast and price target.
  • Earnings Growth

    Earnings for Health Catalyst are expected to grow in the coming year, from ($0.33) to ($0.29) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Health Catalyst is -3.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Health Catalyst is -3.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Health Catalyst has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Health Catalyst's valuation and earnings.
  • Percentage of Shares Shorted

    4.96% of the float of Health Catalyst has been sold short.
  • Short Interest Ratio / Days to Cover

    Health Catalyst has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Health Catalyst has recently increased by 24.05%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Health Catalyst does not currently pay a dividend.

  • Dividend Growth

    Health Catalyst does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.96% of the float of Health Catalyst has been sold short.
  • Short Interest Ratio / Days to Cover

    Health Catalyst has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Health Catalyst has recently increased by 24.05%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Health Catalyst has a news sentiment score of 1.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Health Catalyst this week, compared to 4 articles on an average week.
  • MarketBeat Follows

    Only 1 people have added Health Catalyst to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Health Catalyst insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $299,572.00 in company stock.

  • Percentage Held by Insiders

    Only 2.50% of the stock of Health Catalyst is held by insiders.

  • Percentage Held by Institutions

    85.00% of the stock of Health Catalyst is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Health Catalyst's insider trading history.
Receive HCAT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Health Catalyst and its competitors with MarketBeat's FREE daily newsletter.

HCAT Stock News Headlines

Partner with Elon Musk on Project Colossus… Before May 1st
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.
J.P. Morgan Reaffirms Their Buy Rating on Health Catalyst (HCAT)
See More Headlines

HCAT Stock Analysis - Frequently Asked Questions

Health Catalyst's stock was trading at $7.07 at the beginning of the year. Since then, HCAT shares have decreased by 38.8% and is now trading at $4.33.
View the best growth stocks for 2025 here
.

Health Catalyst, Inc. (NASDAQ:HCAT) issued its earnings results on Wednesday, November, 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by $0.03. The business's quarterly revenue was up 3.5% compared to the same quarter last year.

Health Catalyst (HCAT) raised $129 million in an IPO on Thursday, July 25th 2019. The company issued 6,000,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, J.P. Morgan and William Blair acted as the underwriters for the IPO and Piper Jaffray, Evercore ISI, SVB Leerink and SunTrust Robinson Humphrey were co-managers.

Shares of HCAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Health Catalyst investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY), Voyager Therapeutics (VYGR) and DiamondRock Hospitality (DRH).

Company Calendar

Last Earnings
11/06/2024
Today
4/01/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Computer programming, data processing, & other computer related
Sub-Industry
Computer Software
Current Symbol
NASDAQ:HCAT
Fax
N/A
Employees
1,200
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.27
High Stock Price Target
$16.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+114.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
11 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-118,150,000.00
Pretax Margin
-26.25%

Debt

Sales & Book Value

Annual Sales
$306.58 million
Price / Cash Flow
N/A
Book Value
$6.38 per share
Price / Book
0.68

Miscellaneous

Free Float
59,327,000
Market Cap
$304.01 million
Optionable
Optionable
Beta
1.41
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:HCAT) was last updated on 4/1/2025 by MarketBeat.com Staff
From Our Partners